Richard Kim, MD

Articles

Dr Kim on the Rationale For Investigating the Use of Regorafenib in mCRC

January 22nd 2024

Richard Kim, MD, discusses data from a real-world investigation of long-term responses with regorafenib in patients with metastatic colorectal cancer.

Dr Kim on Ongoing and Planned Research in HCC at Moffitt Cancer Center

January 17th 2024

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

Dr Kim on Selecting Between Frontline Immunotherapy-Based Regimens in HCC

January 12th 2024

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Dr Kim on a Case Study of a Patient With HCC

January 3rd 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

Dr Kim on the Investigation of RLY-4008 in FGFR2+ Cholangiocarcinoma

May 25th 2023

Richard Kim, MD, discusses the investigation of RLY-4008 for the treatment of patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Dr. Kim on The Evaluation of TKI/Immunotherapy Combos in HCC

November 11th 2022

Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.

Dr. Kim on the Evolution of Frontline Treatment in HCC

October 11th 2022

Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.

Pivotal Trial Results Look to Shake Up HCC Treatment

October 18th 2021

Hepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.

Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC

September 14th 2020

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Dr. Kim on the Evolving Treatment Landscape of Advanced HCC

August 14th 2020

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

July 3rd 2020

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Dr. Kim on Immunotherapy in CRC

December 18th 2019

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Kim on the Potential of Ramucirumab in Advanced HCC

April 26th 2019

Richard Kim, MD, assistant professor of oncology at University of South Florida College of Medicine, medical oncologist in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses the potential of ramucirumab in the treatment of advanced hepatocellular carcinoma.

Dr. Kim on Role of Frontline Immunotherapy in Advanced HCC

April 8th 2019

Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.

Dr. Kim on Administering Aflibercept in mCRC

February 19th 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Dr. Kim on the Investigation of Regorafenib in mCRC

January 31st 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.